F. Yakes

发表

PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization

Carlos L. Arteaga, J. Baselga, F. Rojo, 2002, Nature Medicine.

Cyclin-Dependent Kinase Inhibitor P27Kip1 Is Required for Mouse Mammary Gland Morphogenesis and Function

A. Lenferink, C. Arteaga, F. Yakes, 2001, The Journal of cell biology.

CM101 treatment overrides tumor-induced immunoprivilege leading to apoptosis.

F. Sun, F. Yakes, C. Hellerqvist, 2000, Cancer research.

Functional studies on the anti-pathoangiogenic properties of CM101

K. Washington, D. Page, F. Yakes, 2004, Angiogenesis.

Hydrogen peroxide- and peroxynitrite-induced mitochondrial DNA damage and dysfunction in vascular endothelial and smooth muscle cells.

B. Van Houten, M. Runge, S. Ballinger, 2000, Circulation research.

PCR-Based Assays for the Detection and Quantitation of DNA Damage and Repair

F. Yakes, B. V. Houten, Yiming Chen, 1996 .

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

G. Mills, N. Rosen, P. Dennis, 2003, Oncogene.

Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases Experimental Therapeutics, Molecular Targets, and Chemical Biology

K. Yamaguchi, J. Greshock, R. Wooster, 2009 .

Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway

K. Yamaguchi, D. J. Matthews, F. Yakes, 2014, Molecular Cancer Therapeutics.

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

Yongchang Shi, Yu-Chien Chou, K. Yamaguchi, 2011, Molecular Cancer Therapeutics.

Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.

C. Arteaga, F. Yakes, C. Ritter, 2002, Cancer research.

Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress.

B. Van Houten, F. Yakes, B. V. Houten, 1997, Proceedings of the National Academy of Sciences of the United States of America.

In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.

F. Yakes, A. Joly, Lora Zhao, 2013, Thyroid : official journal of the American Thyroid Association.

Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.

R. Bianco, C. Arteaga, F. Yakes, 2001, Cancer research.

HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer.

C. Arteaga, F. Yakes, S. Moulder, 2002, Seminars in oncology.

The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models

K. Yamaguchi, D. J. Matthews, F. Yakes, 2015, Molecular Cancer Therapeutics.

Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.

K. Yamaguchi, J. Greshock, R. Wooster, 2009, Cancer research.

Tyrosine kinase inhibitors: rationale, mechanisms of action, and implications for drug resistance.

A. Lenferink, C. Arteaga, F. Yakes, 2001, Seminars in oncology.

Identification of a novel membrane protein, HP59, with therapeutic potential as a target of tumor angiogenesis.

D. Page, R. Lloyd, F. Yakes, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Inhibition of the T790M Gatekeeper Mutant of the Epidermal Growth Factor Receptor by EXEL-7647

F. Yakes, A. Joly, J. Martini, 2007, Clinical Cancer Research.

The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors.

Wei Xu, Wei Cheng, F. Yakes, 2012, Bioorganic & medicinal chemistry letters.

The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma

Stephen T. C. Wong, P. L. Bergsagel, C. Mitsiades, 2017, Molecular Cancer Therapeutics.

Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083).

Daniel J. Anderson, M. Rolfe, F. Yakes, 2015, Journal of medicinal chemistry.

Targeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein Homeostasis.

J. Weissman, Daniel J. Anderson, M. Rolfe, 2015, Cancer cell.

Epidermal Growth Factor Receptor ( HER 1 ) Tyrosine Kinase Inhibitor ZD 1839 ( Iressa ) Inhibits HER 2 / neu ( erb B 2 )-overexpressing Breast Cancer Cells in Vitro and in Vivo 1

R. Bianco, C. Arteaga, F. Yakes, 2001 .

ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.

A. Lenferink, C. Arteaga, F. Yakes, 2001, Cancer research.

Mutations associated with base excision repair deficiency and methylation-induced genotoxic stress

Samuel H. Wilson, L. Samson, B. Van Houten, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Up-regulation of base excision repair correlates with enhanced protection against a DNA damaging agent in mouse cell lines.

B. Van Houten, S. H. Wilson, J. Horton, 1998, Nucleic acids research.

Preclinical Development Cabozantinib ( XL 184 ) , a Novel MET and VEGFR 2 Inhibitor , Simultaneously Suppresses Metastasis , Angiogenesis , and Tumor Growth

K. Yamaguchi, J. Lesch, F. Yakes, 2011 .

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

K. Yamaguchi, F. Yakes, A. Joly, 2011, Molecular Cancer Therapeutics.